JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis

Jennifer R Lynch, Basit Salik, Patrick Connerty, Binje Vick, Halina Leung, Aster Pijning, Irmela Jeremias, Karsten Spiekermann, Toby Trahair, Tao Liu, Michelle Haber, Murray D Norris, Andrew J Woo, Philip Hogg, Jianlong Wang, Jenny Y Wang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Abnormal metabolism is a fundamental hallmark of cancer and represents a therapeutic opportunity, yet its regulation by oncogenes remains poorly understood. Here, we uncover that JMJD1C, a jumonji C (JmjC)-containing H3K9 demethylase, is a critical regulator of aberrant metabolic processes in homeobox A9 (HOXA9)-dependent acute myeloid leukemia (AML). JMJD1C overexpression increases in vivo cell proliferation and tumorigenicity through demethylase-independent upregulation of a glycolytic and oxidative program, which sustains leukemic cell bioenergetics and contributes to an aggressive AML phenotype in vivo. Targeting JMJD1C-mediated metabolism via pharmacologic inhibition of glycolysis and oxidative phosphorylation led to ATP depletion, induced necrosis/apoptosis and decreased tumor growth in vivo in leukemias co-expressing JMJD1C and HOXA9. The anti-metabolic therapy effectively diminished AML stem/progenitor cells and reduced tumor burden in a primary AML patient-derived xenograft. Our data establish a direct link between drug responses and endogenous expression of JMJD1C and HOXA9 in human AML cell line- and patient-derived xenografts. These findings demonstrate a previously unappreciated role for JMJD1C in counteracting adverse metabolic changes and retaining the metabolic integrity during tumorigenesis, which can be exploited therapeutically.

Original languageEnglish
Pages (from-to)1400-1410
Number of pages11
JournalLeukemia
Volume33
Issue number6
DOIs
Publication statusE-pub ahead of print - 8 Jan 2019

Fingerprint Dive into the research topics of 'JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis'. Together they form a unique fingerprint.

Cite this